Literature DB >> 10851182

Biogenic amine transporters: regulation in flux.

R D Blakely1, A L Bauman.   

Abstract

Following vesicular release, the biogenic amine neurotransmitters dopamine, norepinephrine and serotonin are actively cleared from extracellular spaces by presynaptic transporters. These transporters interact with multiple psychoactive agents including cocaine, amphetamines and antidepressants. Recent findings indicate that amine reuptake is likely to be a tightly regulated component of synaptic plasticity rather than a constitutive determinant of transmitter clearance. Protein kinase C activation and transporter phosphorylation have been linked to regulatory protein trafficking, and both phosphorylation and trafficking may be influenced by transporter ligands. Recognition that transmitters, antagonists and second messengers can modify the intrinsic activity, surface expression or protein levels of amine transporters raises new questions about the fundamental nature of drug actions in vivo. The theory that dysregulation of transporters may contribute to disease states is supported by the recent discovery that a coding mutation in the human norepinephrine transporter contributes to orthostatic intolerance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851182     DOI: 10.1016/s0959-4388(00)00088-x

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  55 in total

1.  Substrates regulate gamma-aminobutyric acid transporters in a syntaxin 1A-dependent manner.

Authors:  Michael W Quick
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

Review 2.  Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6.

Authors:  Nian-Hang Chen; Maarten E A Reith; Michael W Quick
Journal:  Pflugers Arch       Date:  2003-04-29       Impact factor: 3.657

3.  Switching between the two action modes of the dual-affinity nitrate transporter CHL1 by phosphorylation.

Authors:  Kun-Hsiang Liu; Yi-Fang Tsay
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

Review 4.  Is there a SERT-ain association with IBS?

Authors:  M Camilleri
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

5.  Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle.

Authors:  Claus Juul Loland; Lene Norregaard; Thomas Litman; Ulrik Gether
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

Review 6.  Physiological genomics of antidepressant targets: keeping the periphery in mind.

Authors:  R D Blakely
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

7.  Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter.

Authors:  Manuel Miranda; Kalen R Dionne; Tatiana Sorkina; Alexander Sorkin
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

8.  Enhanced activity of human serotonin transporter variants associated with autism.

Authors:  Harish C Prasad; Jennifer A Steiner; James S Sutcliffe; Randy D Blakely
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-01-27       Impact factor: 6.237

9.  Dopamine transporter down-regulation following repeated cocaine: implications for 3,4-methylenedioxymethamphetamine-induced acute effects and long-term neurotoxicity in mice.

Authors:  I Peraile; E Torres; A Mayado; M Izco; A Lopez-Jimenez; J A Lopez-Moreno; M I Colado; E O'Shea
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

10.  Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions.

Authors:  Christian Bjerggaard; Jacob U Fog; Hanne Hastrup; Kenneth Madsen; Claus J Loland; Jonathan A Javitch; Ulrik Gether
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.